Merial, Inc v Intervet International B.V

Link copied
Case Copied 42 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Merial, Inc v Intervet International B.V. [2018] APO 52

Patent Application:                   2011268899

Title:Injectable formulation of a macrocyclic lactone and levamisole

Patent Applicant:  Intervet International B.V

Opponent:  Merial, Inc

Delegate:  K. Wagg

Decision Date:  17 August 2018

Hearing Date:  22 May 2018, in Canberra

Catchwords:  PATENTS - – s59 – grounds of novelty, inventive step, fair basis and utility –all grounds unsuccessful – variation in costs due to amendment

Representation:  Patent attorneys for the Applicant:  David Myers & Matthew Stewart

Counsel for the Opponent:  Christian Dimitriadis SC & Clare Cunliffe

Patent attorneys for the Opponent: Marcus Caulfield & Corrine Porter

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2011268899

Title:Injectable formulation of a macrocyclic lactone and levamisole

Patent Applicant:  Intervet International B.V.

Date of Decision:  17 August 2018

DECISION

The Opposition is unsuccessful.  Subject to appeal, I direct the application proceed to grant.

Costs according to Schedule 8 are awarded against the applicant until the date of advertisement of allowance of the amendment to the specification (9 October 2017) and against the opponent thereafter.

REASONS FOR DECISION

Background

  1. Patent application 2011268899 (the application) is the Australian national phase entry of PCT/EP2011/060535, which was filed on 23 June 2011 and claims a priority date of 24 June 2010. Examination was requested on 11 April 2013. Consequently, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Raising the Bar) do not apply to the present application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. Any subsequent references to sections of the Patents Act relate to the Patents Act 1990 prior to amendment by the Raising the Bar Act. A similar qualification applies to references to the Patents Regulations 1991.

  2. The applicant is Intervet International B.V. (the Applicant). The application was examined and advertised as accepted by the Commissioner on 7 July 2016. Merial Inc. (the Opponent) filed a notice of opposition to grant on 7 October 2016. After evidence in support was filed, the Applicant sought leave to amend the specification, including the claims, on 19 June 2017. Those amendments were allowed on 9 October 2017.  The Statement of Grounds and Particulars was substantively amended in response on 27 September 2017 (Amended SGP)

  3. A hearing was held on 22 May 2018 in Canberra to decide the opposition.  The Opponent was represented by Christian Dimitriadis of counsel, accompanied by Clare Cunliffe,  with Marcus Caulfield and Corrine Porter of FB Rice.  The Applicant was represented by David Myers of Spruson & Ferguson, accompanied by Matthew Stewart.

  4. The Amended SGP identified 8 grounds of opposition. At the hearing the following grounds were pressed:

    oLack of Novelty

    oLack of Inventive Step

    oInutility

    oLack of Fair Basis

    Standard of Proof

  5. The onus of proof in this opposition proceeding rests with the Opponent, who must establish that it is clear or…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merial, Inc v Intervet International B.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] APO 52
Decision Date

CaseChat Overview and Summary

The decision in Merial, Inc v Intervet International B.V. [2018] APO 52 was handed down by K. Wagg, a Delegate of the Commissioner of Patents, on 17 August 2018. The decision concerned a patent application for an injectable formulation of a macrocyclic lactone and levamisole, filed by Intervet International B.V. and opposed by Merial, Inc. The key issues considered by the Delegate were whether the patent claims lacked novelty, inventive step, fair basis and utility. The Delegate found that the patent claims were not lacking novelty, inventive step, fair basis or utility. The Applicant was awarded costs up until the date of advertisement of allowance of the amendment to the specification (9 October 2017) and the Opponent was awarded costs thereafter. The decision was subject to appeal.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.